Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Immunitybio Inc

Healthcare US IBRX

7.085USD
-0.205(2.81%)

Last update at 2026-06-05T15:32:00Z

Day Range

7.037.29
LowHigh

52 Week Range

1.2510.53
LowHigh

Fundamentals

  • Previous Close 7.29
  • Market Cap4509.02M
  • Volume3825274
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-326.59299M
  • Revenue TTM0.30M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.24M
  • Diluted EPS TTM-1.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -583.89200M -417.28600M -349.83900M -226.03300M -160.26300M
Minority interest 0.74M -0.75300M -3.05800M 1.32M 3.65M
Net income -583.19600M -417.32000M -349.84800M -224.18700M -160.15800M
Selling general administrative 122.72M 102.71M 135.26M 27.25M 18.07M
Selling and marketing expenses - - - - 28.39M
Gross profit -17.89000M -23.95200M 0.93M -8.54200M -6.81000M
Reconciled depreciation 19.17M 18.26M 14.24M 12.74M 14.04M
Ebit -361.36400M -351.29800M -330.28000M -220.88000M -156.25100M
Ebitda -342.85200M -343.97800M -316.30400M -195.12800M -139.97600M
Depreciation and amortization 18.51M 7.32M 13.98M 25.75M 16.27M
Non operating income net other - -2.47300M -4.71000M -0.75200M -
Operating income -361.36400M -351.29800M -330.28000M -220.88000M -156.25100M
Other operating expenses 361.99M 350.86M 331.21M 210.82M 158.45M
Interest expense 129.20M 63.52M 14.85M 9.07M 5.92M
Tax provision 0.03M 0.03M 0.00900M 0.00500M -0.09700M
Interest income 2.00M 2.71M 0.84M 1.18M 1.62M
Net interest income -123.63300M -60.80700M -14.01300M -7.34900M -3.15600M
Extraordinary items - - - - -
Non recurring - 0.68M - - -
Other items - - - - -
Income tax expense -0.04000M 0.03M 0.00900M -1.84600M -0.10500M
Total revenue 0.62M 0.24M 0.93M 0.60M 2.20M
Total operating expenses 343.47M 350.86M 331.21M 210.82M 158.45M
Cost of revenue 18.51M 24.19M - 9.15M 9.01M
Total other income expense net -222.52800M -65.98800M -19.55900M -5.15300M -4.01200M
Discontinued operations - - - - -
Net income from continuing ops -458.76400M -417.32000M -349.84800M -92.38300M -160.15800M
Net income applicable to common shares - -416.56700M -346.79000M -129.04100M -91.42300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 504.45M 362.36M 468.91M 221.38M 143.12M
Intangible assets 17.09M 20.00M 1.42M 1.46M -
Earning assets - - - - -
Other current assets 24.45M 5.15M 15.90M 13.65M 3.80M
Total liab 1090.39M 812.18M 712.82M 339.87M 22.44M
Total stockholder equity -586.98700M -447.32700M -242.17300M -119.80800M 120.68M
Deferred long term liab - - 0.16M - -
Other current liab 42.20M 45.29M 55.33M 51.61M 9.81M
Common stock 0.07M 0.04M 0.04M 0.04M 0.01000M
Capital stock 0.07M 0.04M 0.04M 0.04M -
Retained earnings -2961.68400M -2378.48800M -1961.92100M -1615.13100M -662.19100M
Other liab - 22.03M 0.41M 1.56M 8.28M
Good will - - - - -
Other assets - 6.63M 6.38M 7.61M 7.01M
Cash 265.45M 104.64M 181.10M 34.91M 15.51M
Cash and equivalents - - - - -
Total current liabilities 58.28M 500.86M 369.00M 68.13M 11.56M
Current deferred revenue 0.10M - - - -
Net debt 618.22M 619.13M 464.56M 240.63M -0.66000M
Short term debt 6.78M 434.55M 302.25M 5.01M -
Short long term debt - 431.90M 299.24M - -
Short long term debt total 883.68M 723.77M 645.66M 275.55M 14.85M
Other stockholder equity 2374.62M 1930.94M 1719.70M 1495.16M 801.47M
Property plant equipment - 143.66M 82.86M 28.96M 27.78M
Total current assets 294.08M 140.58M 334.35M 111.71M 55.76M
Long term investments 0.89M 0.84M 0.82M 11.40M -
Net tangible assets - -467.33000M -243.59300M -236.52700M -118.60900M
Short term investments 1.01M 2.54M 136.01M 61.15M 36.14M
Net receivables 3.17M 1.89M 1.33M 2.00M 0.30M
Long term debt 681.54M 241.27M 306.35M 254.35M -
Inventory - 26.35M - - -
Accounts payable 9.20M 21.02M 11.42M 11.51M 1.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - -2.49300M -1.74000M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01000M 0.18M 0.00400M 0.12M -18.60700M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.01M 0.01000M
Preferred stock total equity - - - - -
Retained earnings total equity - -2378.48800M -1961.92100M -754.57400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.49M 6.63M 7.20M 7.08M 5.88M
Deferred long term asset charges - - - - -
Non current assets total 210.37M 221.78M 134.56M 109.67M 87.37M
Capital lease obligations 45.19M 50.60M 40.08M 21.19M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 126.69M -71.82100M -0.19300M -0.49900M 35.03M
Change to liabilities 12.10M 1.47M 0.29M 1.52M -0.06900M
Total cashflows from investing activities 27.30M -84.88600M -1.37100M -6.31500M 25.68M
Net borrowings 174.12M 338.50M 63.70M 47.67M 35.76M
Total cash from financing activities 233.61M 505.44M 150.68M 114.28M -0.77100M
Change to operating activities -16.00100M -15.39500M 14.15M -0.50800M -2.11300M
Net income -417.32000M -349.84800M -224.18700M -160.15800M -96.22600M
Change in cash -76.31500M 146.19M -40.88600M -19.29900M -7.05100M
Begin period cash flow 181.28M 35.09M 75.98M 95.28M 24.05M
End period cash flow 104.97M 181.28M 35.09M 75.98M 17.00M
Total cash from operating activities -337.50900M -274.41900M -171.72400M -152.10900M -63.38100M
Issuance of capital stock 60.43M 164.53M 86.30M 30.00M -
Depreciation 18.26M 14.24M 12.74M 14.04M 9.55M
Other cashflows from investing activities -21.22900M 20.50M -17.95000M 25.64M 70.20M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 60.50M 171.43M 86.97M -2.50100M -0.22800M
Other cashflows from financing activities 173.24M 340.91M 64.37M 86.78M -0.06600M
Change to netincome 29.00M 58.33M 12.75M -0.67200M 14.87M
Capital expenditures 99.39M 33.56M 1.67M 4.29M 13.10M
Change receivables - - - - -
Cash flows other operating 2.85M 1.40M 1.12M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -76.59900M 146.14M -4.06700M - -
Change in working capital -8.00100M -19.11200M 16.36M -15.63600M -50.07800M
Stock based compensation 40.18M 57.18M 2.19M 3.42M 23.38M
Other non cash items 29.38M 23.13M 24.11M 6.23M 50.48M
Free cash flow -436.90000M -307.98200M -173.39300M -156.39600M -76.48300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IBRX
Immunitybio Inc		 -0.205 2.81% 7.08 - - 5561.87 - 6301.85 -8.9865
NVO
Novo Nordisk A/S		 -0.015 0.03% 43.73 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.0037 0.0084% 44.19 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.17 1.62% 448.90 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.53 1.20% 636.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Immunitybio Inc

3530 John Hopkins Court, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc. Exec. Chairman, Global Chief Scientific & Medical Officer 1953
Mr. Richard Gerald Adcock Pres, CEO & Director 1969
Mr. David C. Sachs CFO, Principal Financial Officer & Principal Accounting Officer 1978
Dr. Leonard S. Sender M.D. Chief Operating Officer NA
Mr. Jason R. Liljestrom Gen. Counsel & Corp. Sec. 1983
Ms. Sarah Singleton Chief Communications Officer NA
Dr. Sandeep K. Reddy M.D. Chief Medical Officer NA
Dr. Barry J. Simon M.D. Chief Corp. Affairs Officer & Director 1965
Dr. Hans Georg Klingemann M.D., Ph.D. Chief Science Officer of Cellular 1950
Ms. Helen Luu Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.